Multiparametric Assessment to Investigate Prognostic Factors for Disea
Multiparametric Clinical, Radiological, Neuropsychological, and Neurophysiological Assessment to Investigate Prognostic Factors for Disease Evolution and Treatment Response in MS: a Prospective Study.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Multiparametric assessment
What it measured
Main measures
Predictors of disease evolution
3 years
Disability progressionevaluation of evolutionary patterns of cognitive status (impaired vs non impaired)/changes from baseline
3 years
Thinking and memorybaseline predictors of future cognitive impairment
3 years
Thinking and memory
Other measures (2)
alteration in strategic white matter tracts at the early stages of RRMS, in patients with and without cognitive impairment
3 years
MRI lesionsThinking and memorypredictive role of mEPS in predicting future disability
3 years
Disability progressionMyelin repairNerve conduction tests
Who could take part
Relapsing MS · 18 to 50
Show the full criteria
Inclusion criteria
* active MS, according to the Lublin criteria * disease duration \< 10 years before initiating or changing a disease-modifying therapies, * relapse- and steroid-free for at least 1 month before MRI acquisition * between 18-50 years old * having given informed consent * with no significant comorbidity other than MS or substance abuse that could interfere with cognitive performances
Exclusion criteria
* progressive forms of MS
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This prospective study combining non conventional MRI techniques, neuropsychological screening tools, and a neurophysiological work-up using a sensitive and validated battery, will evaluate the predictive value of these measures and will explore the changes of the cognitive scores from baseline.
Loading reviews and guidelines…
History
Started
Jun 2022
Main results due
Jun 2026
Finished
Jun 2026